Recent developments highlight Adaptive Biotechnologies' Q3 earnings and revenue surpassing expectations, continued revenue growth, expanded clinical adoption of clonoSEQ, and strategic partnerships enhancing immune medicine capabilities.

• Adaptive Biotechnologies reported Q3 earnings and revenues exceeding estimates, reflecting ongoing growth in its MRD business and clinical adoption [N1].
• Key Q3 metrics indicate continued expansion of clonoSEQ test volumes and biopharmaceutical collaborations supporting drug development [N2].
• The company was featured among biotech stocks delivering significant gains, highlighting key catalysts in its immune medicine platform [N3].
• Q2 results showed a widening net loss despite revenue growth, indicating ongoing investment in growth initiatives [N4].
• Q2 earnings reports emphasized key operational metrics and revenue beats, supporting business momentum [N5][N6].
• Q2 earnings call highlighted strategic priorities and clinical trial progress for clonoSEQ and immune medicine applications [N7].
• Market commentary noted potential negative earnings trends ahead of earnings releases, reflecting financial volatility [N8].

Adaptive Biotechnologies has demonstrated growth in its MRD business with expanding clinical adoption, payor coverage, and integration into electronic medical records, supporting broader clinical utility. Its partnerships with biopharmaceutical companies and Pfizer enhance its immune medicine capabilities and pipeline potential. The company's proprietary platform and large immunomics database position it to address multiple immune-related diseases, including cancer and autoimmunity. Recent clinical trial data and expanded use cases for clonoSEQ support its role in guiding treatment decisions and drug development. Financial improvements in revenue and cash flow metrics indicate operational progress.

Risks include the complexity of immune system biology and the challenge of translating proprietary data into commercially successful products beyond MRD testing. The discontinuation of certain therapeutic programs suggests prioritization challenges. Regulatory, reimbursement, and competitive pressures in diagnostics and immunotherapy markets may impact growth. The company's net income remains modest relative to scale, and reliance on biopharmaceutical partnerships introduces dependency risks. Market adoption of novel immune medicine applications may face scientific and commercial hurdles.

Adaptive Biotechnologies' moat is built on its proprietary immune medicine platform that combines next-generation sequencing, computational biology, and machine learning to decode the adaptive immune system at scale. Its clonoSEQ assay is FDA-authorized with industry-leading sensitivity for minimal residual disease detection in lymphoid malignancies, supported by a large clinical immunomics database and integration into clinical workflows and biopharmaceutical trials. The company's extensive proprietary datasets, including millions of TCR-antigen mappings, and its partnerships with major biopharmaceutical firms create high barriers to entry. The platform's ability to provide precise, personalized immune insights and its regulatory approvals contribute to a defensible competitive position in immune diagnostics and therapeutic discovery.

• Scientific and Technical Complexity: The adaptive immune system's complexity poses challenges in accurately decoding and translating immune data into clinically actionable products.
• Regulatory and Reimbursement Risks: FDA authorization and payor coverage are critical for clinical adoption; changes or delays could impact revenue growth.
• Competitive Landscape: Other companies developing immune diagnostics and therapies may compete, potentially affecting market share and pricing.
• Dependency on Biopharmaceutical Partnerships: The MRD Pharma business and immune medicine collaborations rely on external partners, which may affect revenue stability.
• Financial Performance: While revenue has grown, net income remains modest, and continued investment is required to advance technology and commercial efforts.

• Adaptive Biotechnologies Corp operates an immune medicine platform that decodes the adaptive immune system to develop clinical products and services tailored to individual patients [S1].
• The company reorganized in 2024 into two main businesses: the MRD business focused on minimal residual disease assessment in lymphoid malignancies, and the Immune Medicine (IM) business focused on immune response applications [S1].
• The MRD business includes the clonoSEQ clinical diagnostic test for clinicians and the clonoSEQ assay for biopharmaceutical partners to support drug development [S1].
• clonoSEQ is FDA-authorized for detection and monitoring of MRD in multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, and is available as a CLIA-validated LDT for other lymphoid cancers [S1].
• The MRD business total addressable market is estimated at approximately $6.2 billion, with $5.3 billion from clinical testing [S1].
• The IM business leverages proprietary sequencing, mapping, pairing, and characterization of TCRs and BCRs, with a large clinical immunomics database including over 5 million TCR-antigen matches [S1].
• The IM business offers immune receptor sequencing, data licensing, TCR-antigen prediction models, and target discovery capabilities [S1].
• In autoimmunity, the company has identified autoreactive TCRs in diseases such as multiple sclerosis and type 1 diabetes [S1].
• In 2025, Adaptive Biotechnologies reported revenue of $277 million, up from $179 million in 2024, driven primarily by the MRD business which grew $66.8 million [S1].
• Net cash used in operations was $46 million in 2025, a 52% reduction from $95.2 million in 2024 [S1].
• As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $227.2 million excluding cash held by a subsidiary [S1].
• In 2025, the MRD business delivered 105,587 clonoSEQ tests, a 39% increase year-over-year [S1].
• Payor coverage expanded to over 300 million lives in ALL and MM, over 270 million lives in CLL, and over 90 million lives in DLBCL, with Medicare coverage for recurrence monitoring in MCL [S1].
• clonoSEQ MRD testing is integrated into 173 sites on Epic's EMR system and other EMRs to facilitate routine patient access [S1].
• The clonoSEQ assay is used in over 180 active clinical trials by more than 40 biopharmaceutical partners, including over 100 trials with MRD as a clinical endpoint [S1].
• In December 2025, the company entered two non-exclusive agreements with Pfizer to leverage its TCR discovery platform for rheumatoid arthritis and broader immunology research [S1].
• The company increased paired TCRs to antigens from over two million to over five million, covering over 20,000 antigens and nearly 50 HLA types [S1].
• The company discontinued investments in a TCR-depleting antibody program in ankylosing spondylitis to prioritize data development and diagnostics [S1].
• The immunosequencing platform uses proprietary NGS-based methods to sequence TCRs and BCRs, enabling sensitive detection of malignant cells and immune repertoire analysis [S1].
• The clonoSEQ test process involves DNA extraction, amplification, sequencing, and proprietary data analysis to identify and quantify malignant cells with sensitivity of 1 in 1,000,000 cells [S1].
• The platform supports clinical decision-making by tracking MRD status to guide treatment and drug development [S1].
• Recent clinical studies using clonoSEQ data include the MIDAS Phase 3 trial in multiple myeloma supporting MRD-guided treatment decisions and the EndRAD Phase 2 study in B-ALL guiding conditioning regimens [S1].
• As of September 30, 2026, Adaptive Biotechnologies reported cash and equivalents of $75.6 million, current assets of $392.7 million, and current liabilities of $98.97 million, resulting in a current ratio of 3.97 and a cash ratio of 0.76 [S2].
• Net income for the quarter ending September 30, 2026, was $2.88 million with basic and diluted EPS of $0.02 [S2].
• Recent news highlights include Q3 earnings and revenues surpassing estimates, continued revenue growth, and expanded clinical and biopharmaceutical partnerships [N1][N2][N3][N4][N5][N6][N7][N8].